Apr 27, 2023

SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism Explore

Mar 21, 2023

Exeliom Biosciences Announces First Patient Enrolled in Phase 1 Study for the Maintenance in Remission in Adult Patients With Mild to Moderate Crohn's Disease

Clinical Trial Live Biotherapeutics Crohn's Disease Belgium

Feb 24, 2022

Exeliom Biosciences announces approval of Clinical Trial Application from the Belgian Agency for Single Strain Live Biotherapeutic EXL01 (Faecalibacterium prausnitzii) for the treatment of Crohn’s Disease

Manufacturing

May 7, 2021

Exeliom Biosciences opens pilot manufacturing unit for Live Biotherapeutics (LBPs) thanks to European H2020 Accelerator Program

H2020 Accelerator Program Live Biotherapeutics Manufacturing

Aug 3, 2020

Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council

Deeptech Bpifrance Microbiome

Aug 12, 2019

Exeliom Biosciences is awarded 1.8M€ DeepTech grant from Bpifrance to advance its lead program

Nextbiotix Exeliom Biosciences

Feb 15, 2019

Nextbiotix becomes Exeliom Biosciences

I-lab2018 Bpifrance

Jul 23, 2018

Exeliom Biosciences is awarded I-Lab2018 from Bpifrance

Series-A Biotech Exeliom Biosciences Nextbiotix

Jul 5, 2018

Exeliom Biosciences (formerly Nextbiotix) raises €7 million to tackle inflammatory bowel diseases

Wilco

Sep 27, 2017

Exeliom Biosciences joins Wilco Incubator

Paris Biotech Santé

Sep 25, 2017

Exeliom Biosciences joins Paris Biotech Santé Incubator

newsroom

upcoming events

contact

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.